AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01643135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
Study NCT01643135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Study NCT02161445 — intervention group
Intervention type: DEVICE
Intervention: the acoustic cardiographic parameters were calculated
Description: STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
Study NCT01456221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega3 and an hypocaloric diet.
Description: Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
Study NCT01456221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil with an hypocaloric diet.
Description: Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
Study NCT04817904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
Study NCT05612724 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Testing for SARS CoV2 Antigen
Description: Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: Measured in the seated position after 5 minutes rest
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure and Heart Rate
Description: Measured in the seated position after 5 minutes rest
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arterial Stiffness
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study NCT01656642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.
Study NCT01656642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Oral repeating dose
Study NCT01656642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Stiffness
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study NCT04533295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture and IVF
Description: Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
Study NCT04533295 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture and IVF
Description: Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
Study NCT01125137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Keloid
Description: Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
Study NCT04046783 — intervention group
Intervention type: DEVICE
Intervention: patch
Description: an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central Haemodynamics
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study NCT03967223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel (lete-cel, GSK3377794)
Description: letetresgene autoleucel will be administered.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Central Haemodynamics
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study NCT04091217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
Study NCT04091217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
Study NCT03967223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as the lymphodepleting chemotherapy
Study NCT02598414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-infrared ICG fluorescence imaging
Description: Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
Study NCT02598414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional bowel anastomosis
Description: Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
Study NCT02598414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FireFly™
Description: The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
Study NCT04495660 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
Study NCT04495660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
Study NCT03967223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Passive perceptual stimulation
Description: Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
Study NCT01114893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%
Description: 1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
Study NCT01114893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost Vehicle
Description: 1 drop in each eye 8 times daily for 5 days
Study NCT01114893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost (Groups A, B and C)
Description: 1 drop in each eye 8 times daily for 5 days
Study NCT03405454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
Study NCT03405454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: chemotherapy treatment will be administered as per local institutional guidelines
Study NCT01759277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Femoral perineural local anesthetic infusion
Description: The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive perceptual stimulation
Description: Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Task A not B
Description: Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task A not B
Description: Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VSWMT task
Description: VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSWMT task
Description: VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perceptual Go-No-Go
Description: Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Go-No-Go
Description: Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Verbal memory task
Description: Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal memory task
Description: Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The sensory room
Description: The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
Study NCT04495660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The sensory room
Description: The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
Study NCT01759277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Adductor Canal perineural local anesthetic infusion
Description: The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
Study NCT00355797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Stimulation (CLS)
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid Intima Media Thickness
Description: Measurements will be repeated three times, and the average of the median values will be recorded
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carotid Intima Media Thickness
Description: Measurements will be repeated three times, and the average of the median values will be recorded
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm blood flow studies
Description: Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Forearm blood flow studies
Description: Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant medication check
Description: Review of medication taken by the participant
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Concomitant medication check
Description: Review of medication taken by the participant
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication compliance check (Pill count)
Description: Ensure prescribed statin has been taken
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication compliance check (Pill count)
Description: Ensure prescribed statin has been taken
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: Check overall health
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical examination
Description: Check overall health
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical history
Description: Review of volunteers medial history
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical history
Description: Review of volunteers medial history
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AE/SAE review & reporting
Description: Monitor safety from the point of consent
Study NCT01101191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet x 1 dose taken without food.
Study NCT01101191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
Study NCT03520127 — intervention group
Intervention type: DEVICE
Intervention: Intact Breast Lesion Excision System (BLES)
Description: Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
Study NCT03556488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: US air bronchogram score
Description: On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment.
Study NCT01650129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
Study NCT01650129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 50
Description: Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
Study NCT04355728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.
Description: UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
Study NCT04355728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle + Heparin along with best supportive care
Description: Best supportive care treatment per the treating hospital protocol.
Study NCT03829800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure® Abbott Nutrition
Description: Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Study NCT03829800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna® Abbott Nutrition
Description: Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Study NCT03829800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diasip® Nutricia Advanced
Description: Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Study NCT03829800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glicolab®
Description: Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
Study NCT01335308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
Study NCT03273972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AE/SAE review & reporting
Description: Monitor safety from the point of consent
Study NCT03273972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing
Description: To be performed at the end of the visit following completion all other study visits
Study NCT03273972 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dosing
Description: To be performed at the end of the visit following completion all other study visits
Study NCT02326883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management
Description: The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
Study NCT04626063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
Study NCT04626063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment